Parkinson's disease, cortical dysfunction, and alpha‐synuclein

The ability to understand how Parkinson's disease neurodegeneration leads to cortical dysfunction will be critical for developing therapeutic advances in Parkinson's disease dementia. The overall purpose of this project was to study the small‐amplitude cortical myoclonus in Parkinson's disease as an in vivo model of focal cortical dysfunction secondary to Parkinson's disease neurodegeneration. The objectives were to test the hypothesis that cortical myoclonus in Parkinson's disease is linked to abnormal levels of α‐synuclein in the primary motor cortex and to define its relationship to various biochemical, clinical, and pathological measures. The primary motor cortex was evaluated for 11 Parkinson's disease subjects with and 8 without electrophysiologically confirmed cortical myoclonus (the Parkinson's disease + myoclonus group and the Parkinson's disease group, respectively) who had premortem movement and cognitive testing. Similarly assessed 9 controls were used for comparison. Measurements for α‐synuclein, Aβ‐42 peptide, and other biochemical measures were made in the primary motor cortex. A 36% increase in α‐synuclein was found in the motor cortex of Parkinson's disease + myoclonus cases when compared with Parkinson's disease without myoclonus. This occurred without significant differences in insoluble α‐synuclein, phosphorylated to total α‐synuclein ratio, or Aβ‐42 peptide levels. Higher total motor cortex α‐synuclein levels significantly correlated with the presence of cortical myoclonus but did not correlate with multiple clinical or pathological findings. These results suggest an association between elevated α‐synuclein and the dysfunctional physiology arising from the motor cortex in Parkinson's disease + myoclonus cases. Alzheimer's disease pathology was not associated with cortical myoclonus in Parkinson's disease. Cortical myoclonus arising from the motor cortex is a model to study cortical dysfunction in Parkinson's disease. © 2011 Movement Disorder Society

[1]  D. Perl,et al.  Parkinson's disease dementia: a diminished role for the Lewy body. , 2009, Parkinsonism & related disorders.

[2]  J. Caviness.  Pathophysiology and treatment of myoclonus. , 2009, Neurologic clinics.

[3]  Dag Aarsland,et al.  Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology , 2009, Alzheimer disease and associated disorders.

[4]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[5]  Jean-Christophe Rochet,et al.  Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. , 2009, Biophysical journal.

[6]  Daniel Sage,et al.  Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.

[7]  K. Maguire-Zeiss.  alpha-Synuclein: a therapeutic target for Parkinson's disease? , 2008, Pharmacological research.

[8]  V. Uversky.  Alpha-synuclein misfolding and neurodegenerative diseases. , 2008, Current protein & peptide science.

[9]  T. Iwatsubo,et al.  Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies , 2008, Experimental Neurology.

[10]  Claudio Soto,et al.  Protein misfolding and neurodegeneration. , 2008, Archives of neurology.

[11]  D. Connor,et al.  The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007 , 2007, Cell and Tissue Banking.

[12]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[13]  R. Bhidayasiri,et al.  Post-hypoxic animal model of myoclonus. , 2007, Parkinsonism & related disorders.

[14]  M. Spillantini,et al.  Physiological and pathological properties of α-synuclein , 2007, Cellular and Molecular Life Sciences.

[15]  K. Beyer.  Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane , 2007, Cell Biochemistry and Biophysics.

[16]  Peter T Lansbury,et al.  Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. , 2007, Journal of molecular biology.

[17]  Y. Itoyama,et al.  Plasma membrane ion permeability induced by mutant α‐synuclein contributes to the degeneration of neural cells , 2006, Journal of neurochemistry.

[18]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[19]  Isidre Ferrer,et al.  Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease , 2005, Journal of neuropathology and experimental neurology.

[20]  H. Braak,et al.  Cognitive status correlates with neuropathologic stage in Parkinson disease , 2005, Neurology.

[21]  I. Alafuzoff,et al.  α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia , 2005, Annals of neurology.

[22]  K. Jellinger.  The association of incident dementia with mortality in PD , 2003, Neurology.

[23]  C. Adler,et al.  Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. , 2002, Parkinsonism & related disorders.

[24]  C. Adler,et al.  Small‐Amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[25]  K. Jellinger,et al.  Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease , 2002, Journal of Neural Transmission.

[26]  G. Glosser,et al.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.

[27]  P J McLean,et al.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.

[28]  B. Hyman,et al.  Membrane Association and Protein Conformation of α-Synuclein in Intact Neurons , 2000, The Journal of Biological Chemistry.

[29]  C. Adler,et al.  Electrophysiological observations in hereditary parkinsonism‐dementia with Lewy body pathology , 2000, Movement disorders : official journal of the Movement Disorder Society.

[30]  J. DeFelipe.  Chandelier cells and epilepsy. , 1999, Brain : a journal of neurology.

[31]  D. Horoupian,et al.  Alzheimer’s disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration , 1999, Acta Neuropathologica.

[32]  J. DeFelipe,et al.  Chandelier cell axons are immunoreactive for GAT‐1 in the human neocortex , 1998, Neuroreport.

[33]  J. Deuchars,et al.  Synaptic interactions in neocortical local circuits: dual intracellular recordings in vitro. , 1997, Cerebral cortex.

[34]  P. Hof,et al.  Motor Cortex Involvement in Presenile Dementia: Report of a Case , 1992, Journal of geriatric psychiatry and neurology.

[35]  K. Maguire-Zeiss.  α -Synuclein: A therapeutic target for Parkinson’s disease? , 2009 .

[36]  Vladimir N Uversky,et al.  Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. , 2007, Journal of neurochemistry.

[37]  K. Beyer.  Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. , 2007, Cell biochemistry and biophysics.

[38]  M. Spillantini,et al.  Physiological and pathological properties of alpha-synuclein. , 2007, Cellular and molecular life sciences : CMLS.

[39]  P. Brown.  Clinical neurophysiology of myoclonus , 2006 .

[40]  J. Caviness.  Chapter 32 The clinical neurophysiology of myoclonus , 2003 .

[41]  Joseph E Parisi,et al.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.

[42]  C. Adler,et al.  Myoclonus in Lewy body disorders. , 2002, Advances in neurology.

[43]  A. Keller,et al.  Characteristics of GABAergic neurons and their synaptic relationships with intrinsic axons in the cat motor cortex. , 2000, Somatosensory & motor research.

[44]  R. Motter,et al.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.